|Title||Will converting naloxone to over-the-counter status increase pharmacy sales?|
|Publication Type||Journal Article|
|Year of Publication||2019|
|Authors||Murphy SM, Morgan JR, Jeng PJ, Schackman BR|
|Journal||Health Serv Res|
|Date Published||2019 Aug|
OBJECTIVE: To estimate the own-price elasticity of demand for naloxone, a prescription medication that can counter the effects of an opioid overdose, and predict the change in pharmacy sales following a conversion to over-the-counter status.
DATA SOURCES/STUDY SETTING: The primary data source was a nationwide prescription claims dataset for 2010-2017. The data cover 80 percent of US retail pharmacies and account for roughly 90 percent of prescriptions filled. Additional covariates were obtained from various secondary data sources.
STUDY DESIGN: We estimated a longitudinal, simultaneous equation model of naloxone supply and demand. Our primary variables of interest were the quantity of naloxone sold, measured as total milligrams sold at pharmacies, and the out-of-pocket price paid per milligram, both measured per ZIP Code and quarter-year.
DATA COLLECTION/EXTRACTION METHODS: Primary data came directly from payers and processors of prescription drug claims.
PRINCIPAL FINDINGS: We found that, on average, a 1 percent increase in the out-of-pocket price paid for naloxone would result in a 0.27 percent decrease in pharmacy sales. We predict that the total quantity of naloxone sold in pharmacies would increase 15 percent to 179 percent following conversion to over-the-counter status.
CONCLUSIONS: Naloxone is own-price inelastic, and conversion to over-the-counter status is likely to lead to a substantial increase in total pharmacy sales.
|Alternate Journal||Health Serv Res|
|PubMed Central ID||PMC6606536|
|Grant List||P30DA040500 / / National Institute on Drug Abuse / |
P30 DA040500 / DA / NIDA NIH HHS / United States
Division:Comparative Effectiveness & Outcomes Research